Introduction
identified as a receptor for N-carboxymethyllysinemodified proteins, one of the major AGE in vivo [1] , but also able to bind other non-glycated molecules, such as S100/calgranulin family of peptides, high mobility group box 1 protein (HMGB1), amyloid-β peptide and macrophage-1 antigen (Mac-1) [2] [3] [4] . Ligand engagement of RAGE leads to the activation of the nuclear transcription factor NF-κB which results in the onset of the inflammatory response [5] . Besides the cell-surface form, RAGE also exists as a soluble circulating molecule (sRAGE), a decoy receptor able to prevent ligand binding at cellular level and therefore the induction of the inflammatory response [6] . Some recent studies demonstrated that increased expression of the cell-surface form promotes inflammation, adipocyte hypertrophy and insulin resistance [7, 8] . Concerning the soluble form, sRAGE has been determined to have an inverse association with obesity, metabolic syndrome, atherosclerosis, coronary artery disease (CAD) and diabetes [9] [10] [11] [12] [13] [14] [15] [16] [17] . These observations suggest sRAGE as a possible marker for metabolic dysfunction and risk. Conversely, in some studies on longterm diabetes (both type 1 and 2), increased sRAGE levels were proposed as a predictive biomarker of cardiovascular diseases (CVDs) and all cause of mortality [15, 18, 19] . In this regard, it needs to be pointed out that there are different circulating RAGE forms contributing to the overall sRAGE levels: the endogenous secretory RAGE (esRAGE), an alternatively spliced form of RAGE, and the cleaved form of the membrane receptor, cRAGE [6, [11] [12] [13] [19] [20] [21] [22] . What is measured and whether the different forms have the same activities may account for some of the differences between the studies.
Accurate assessment of body fat distribution is considered critical for assessing the risk of CVDs, mainly CAD [23, 24] . Although most attention has been traditionally given to the relationship among intra-abdominal fat accumulation and CAD, in the last years epicardial adipose tissue (EAT), the visceral fat located around the heart, received great consideration mainly due to its anatomical proximity to the myocardium and its endocrine activity [25] [26] [27] [28] .
To date, it is unclear whether the lower sRAGE levels observed in obesity [9, 12, 16, 17] are a marker of increased overall adiposity or instead reflect increases in particular visceral fat depots, important in CVDs risk estimation.
Therefore, in a group of adult women without known metabolic disorders we evaluated the relationship between sRAGE and indicators of adiposity, including abdominal subcutaneous (SAT), abdominal visceral (VAT) and epicardial visceral (EAT) adipose tissues, to explore the potential role of sRAGE as an early biomarker of cardiometabolic risk.
Materials and methods

Study population
Forty-seven healthy women referred to the Service of Clinical Nutrition and Cardiometabolic Prevention at the I.R.C.C.S. Policlinico San Donato were enrolled in this study. Inclusion criteria were: female sex, age >18 years, eumenorrhea and signed written informed consent. Individuals who met the following criteria were not eligible for the study: body mass index (BMI) <18.5, chronic illnesses (hematological and rheumatic diseases, inflammatory bowel disease, chronic renal failure, hypercortisolism, diabetes mellitus, hyper or hypothyroidism), history of cancer, smoking, alcohol and drug abuse, and contraindication to magnetic resonance imaging (MRI). The study protocol, conducted in accordance with the declaration of Helsinki as revised in 2013, has been approved by the local ethics committee (ASL Milano 2, protocol 2732), and all participants signed an informed consent before enrollment.
Blood collection
Blood samples were collected after an overnight fasting into pyrogen-free tubes with ethylenediaminetetraacetic acid as anticoagulant. Plasma samples were separated after centrifugation at 1500 g for 15 min and stored at −20 °C until analyses.
Biochemical assays
The quantitative determination of sRAGE concentrations was performed by a commercial human sRAGE immunoassay kit (R&D System, Minneapolis, MN, USA) according to manufacturer's instructions. The minimum detectable dose ranged from 1.23 to 16.14 pg/mL. The maximum intra-and inter-assay coefficient of variations was 4.8 and 8.3 %, respectively.
Other biochemical parameters were assayed as previously reported [23, 29] . LDL cholesterol was calculated with the Friedewald formula. Homeostasis model assessment of insulin resistance (HOMA-IR) index was calculated as follows: HOMA-IR = fasting insulin [μU/ mL] × fasting glucose [mmol/L]/22.5 [30] . The formula used for the lipid accumulation product (LAP) index was: (waist circumference [WC, cm] − 58) × (triglycerides [TG, mmol/L]) [31] .
Anthropometric measures
All participants were measured in light clothing and without shoes. Weight and height were taken with standard scales and stadiometers and recorded to the nearest 0.1 kg and 0.5 cm, respectively. WC and hip circumference were taken with a flexible non-stretchable tape, according to WHO guidelines [32] . BMI and waist-to-hip ratio (WHR) were calculated.
Bioimpedance analysis
Whole body composition was estimated using the Tanita-BC-420-MA Body Composition Analyzer (BIA) (Tanita Europe B.V., Amsterdam, The Netherlands), in the morning, under standardized conditions (prohibition of: alcohol intake and intensive training during the 12 h preceding the measurements, excessive food and drink intake the day before, food and drink intake during the 4 h before the test, measurement during menstruation). Body composition, including body fat mass (FM), was estimated by BIA according to resistance and reactance values, which are measured by the system, and subject's height, sex and age.
Quantification of EAT, VAT and SAT volumes by MRI
MRI was used to determine epicardial fat volume, as previously reported [33, 34] . All examinations were performed using a 1.5-T system (Magnetom Sonata, Siemens Medical Systems, Erlangen, Germany). Subjects remained positioned in the scanner during the entire examination, and a dedicated 4-element phased-array cardiac coil was used. Images were acquired during repeated end-expiratory breath-holds. Electrocardiographically gated cine true fast imaging with steady-state precession sequences (true-FISP) was acquired (bright blood, time of repetition [TR]/time to echo [TE] 45/1.5 ms, slice thickness 8 mm, flip angle 65°, 1 excitation; no inter-slice gap) along the 4-chamber axis to cover the entire cardiac volume. EAT volume was measured using Argus VA50A (Leonardo, Siemens Medical Systems) on a remote workstation. Epicardial fat was measured as the fat deposition between the outer layer of the myocardium and the visceral layer of the pericardium. A radiologist manually segmented true-FISP images of the end-systolic cardiac cycle. The area corresponding to the epicardial fat of each slice was multiplied by slice thickness and then added to each other to obtain the total volume [34] . MRI was also used to determine VAT and SAT [35] . During the same MRI examination, a true-FISP sequence was acquired with the following parameters: TE 4.3 ms, TR 2.15 ms, acquisition time 70 s and slice thickness 5 mm. The field of view was set to encompass both VAT and the SAT. Slices were obtained at the level of L4 vertebral body. VAT and SAT areas were identified by an experienced trained radiologist with a manual segmentation.
Statistical analysis
Qualitative variables are summarized as numbers and percentages; quantitative variables are expressed as mean with standard deviation (SD) or median and interquartile range (IQR). The normality of data distribution was assessed by the Kolmogorov-Smirnov test. T test or Mann-Whitney test were used to compare sRAGE levels after women were classified according to the median value of EAT, VAT and SAT volumes or the WC cutoff value of 80 cm. For group-wise comparison (three groups), ANOVA or Kruskal-Wallis tests followed by Bonferroni or Dunn's tests were used as appropriate. To test the univariate association between sRAGE and the other variables, Pearson (for normally distributed data) or Spearman (for non-normal distributed data) correlation tests were used, as appropriate. Stepwise regression analysis was performed to test the independent association between sRAGE and indices of fat distribution. All statistical analyses were performed using STATISTIX 7.0 (Analytical Software, Tallahassee, FL) and GraphPAd Prism 5.0 biochemical statistical package (GraphPad Software, San Diego, CA). A p value <0.05 was considered significant.
Results
The characteristics of the individuals included in the study are presented in Table 1 Obese women had lower sRAGE levels (640.8, 423.2-1345.0 ng/mL) compared to normal weight (1363.0 ± 693.2 ng/mL, p = 0.022). No differences were observed between overweight (1389.0 ± 617.8 ng/mL) and normal-weight women ( Fig. 1a ; Table 1 ).
After participants were classified according to BMI, all the evaluated anthropometric parameters and indices of adipose tissue distribution, that is EAT, VAT and SAT, were statistically significantly higher in both overweight and obese groups compared to normal weight (Table 1) . Fasting glucose and fasting insulin levels were higher, whereas HDL cholesterol is lower in obese than normal-weight group, but all in the normal ranges (Table 1) . We also observed an increase in HOMA-IR and LAP, two indicators of insulin resistance, according to the obesity status (Table 1) .
Concerning parameters of body fat distribution, we explored sRAGE levels after women were classified according to the median value of EAT (9.2 mm), VAT (21.65 mm) and SAT (300 mm) volumes or the established 1 3 WC cutoff value of 80 cm, which is used to predict cardiovascular risk in European women. sRAGE levels were lower in all the groups with the highest EAT, VAT or SAT volumes compared to the lowest (p < 0.05 for all) (Fig. 1b-d) . Lower sRAGE levels were also observed in the group with WC above the cutoff value of 80 cm (n = 29) (p = 0.048) (Fig. 1e) .
The association of sRAGE with anthropometric and fat distribution parameters was then evaluated using Pearson or Spearman correlation coefficients. sRAGE inversely correlated with BMI, FM, WC and hip circumference (Table 2) . We also observed an inverse association of sRAGE with EAT (r = −0.426, p = 0.003) and VAT (−0.341, p = 0.025), but not with SAT volume (r = −0.197, p = 0.206) ( Table 2) .
HOMA-IR and LAP were observed to be higher in women with depressed sRAGE levels, but their correlations with sRAGE did not reach statistical significance (HOMA-IR: r = −0.252, p = 0.087; LAP: r = −0.252, p = 0.085; Table 2 ).
To emphasize the role of fat distribution, a multiple stepwise regression analysis was then used to investigate the influence of different adipose tissue compartments on sRAGE levels. FM and parameters of fat distribution that were significantly correlated in the univariate analysis were included in the model. EAT volume most correlated with sRAGE, whereas the other indices did not enter the model (Table 3) .
Discussion
Our study suggests that, in a group of healthy women, lower sRAGE levels mainly reflect visceral fat accumulation at the epicardial level rather than total body fat or fat accumulation in other adipose tissue depots. Due to the role of EAT as an important risk factor for CVDs and the fact that our study population is composed by adult women without known metabolic diseases, the existing association observed among sRAGE and EAT suggests a potential role of sRAGE as an early marker of cardiometabolic complications. The inverse correlation between sRAGE and obesity has been suggested in previous studies performed using both in vitro models, RAGE knockout animals as well as in humans, and confirmed also by our study [8, 9, 12, 16, 17, [36] [37] [38] [39] . Monden et al. [8] described the role of RAGE in promoting adipocyte hypertrophy. They observed lower weight, lower epididymal adipose tissue weight and adipocyte size in RAGE-/-mice. In addition, they also described a direct effect of adenoviral RAGE over-expression in promoting 3T3-L1 adipocyte hypertrophy. In the field of human studies, a recent paper from our group suggested that increasing expression of RAGE in EAT is associated with increased tissue thickness [39] . Concerning the circulating form, lower sRAGE levels were associated with increasing BMI and metabolic syndrome, also in proportion to the number of metabolic components, including central obesity, hyperglycemia and blood pressure [9, 12, 16, 21, [40] [41] [42] . Although these studies suggested the existence of an association between sRAGE and central obesity, they utilized WC as a marker of abdominal visceral fat accumulation, not the direct quantification of VAT volume. Differently, we were the first to explore the association between sRAGE levels and indicators of adiposity in a group of healthy premenopausal women, including indicators of visceral adiposity, such as VAT and EAT, directly quantified by MRI. It is well known that adipose tissue distribution, and not adipose tissue per se, is important in CVD risk estimation, and in the last decade, EAT received great consideration in this field mainly due to its anatomical proximity to the myocardium and its endocrine activity.
Currently, there is no consensus on the "gold standard" for the in vivo quantification of EAT, and both computed tomography (CT), and ultrasound and MRI techniques have been used to quantify cardiac fat [43] . Ultrasound is the most widely available, fastest and the least expensive technique for estimating cardiac fat [43] but has the limitation of not being truly volumetric and cannot directly quantify the volume of cardiac fat [44] . Moreover, using ultrasound, it is difficult to distinguish between EAT and pericardial adipose tissue and often this last rather than EAT thickness is reported. In addition, ultrasound evaluation of EAT may be difficult in overweight patients. CT provides a true volumetric visualization and quantification of EAT and pericardial adipose tissue and may provide a more accurate evaluation of fat tissue due to its higher spatial resolution compared with ultrasound and MRI [43, 45] but provides a ionizing radiation exposure. The gold standard for the evaluation of total body fat as well as for ventricular volume and mass is MRI and so the use of MRI is a reliable choice for the assessment of EAT [46] . Moreover, there is a high correlation between measurement of EAT with echocardiography and MRI [45] . For these reasons, in our study, we decided to evaluate EAT with MRI, considering this technique reliable also in overweight and obese patients, without a radiation exposure. For the evaluation of VAT and SAT, the most reliable tools are CT and MRI. MRI can produce high-quality cross-sectional images without ionizing radiation exposure. Therefore, MRI is the first-choice exam for studies performed on young subjects. Total VAT volume of the abdominal compartment by MRI is the gold standard measurement for VAT but is expensive and a long-lasting exam [47] . Maislin et al. in a cohort of 826 subjects, including also overweight and obese subjects, demonstrated that VAT area estimated on a single axial MRI image is highly correlated with VAT volume and is an accurate surrogate for the total VAT volume. Previous publications, also from our group, suggested the potential role of EAT in promoting/accelerating CAD and other CVDs [23, 27, 28, 34] . To be noted, in the present study, we just observed that EAT is the main fat depot influencing sRAGE levels. Considering that sRAGE has been previously suggested as a potential biomarker of metabolic complications and future cardiovascular events, our results prompted us to consider the increased accumulation of visceral fat at the epicardial level one potential explanation of the link between sRAGE and CVDs. To date, the mechanisms of interaction between sRAGE and obesity are still unclear, and our results did not prove the causal relationship between sRAGE and EAT. This remains an interesting area to explore in the future.
The "healthy" characteristic of our group is probably the reason of the lack of association between sRAGE and the biochemical markers of CVD risk observed in other studies [16, 43] . Only HOMA-IR and LAP indices showed a trend of correlation with sRAGE. This finding is a further evidence that sRAGE may be an early marker of metabolic dysfunction. Especially, since the individuals included in the study were young, healthy adults without diabetes, the trend toward higher HOMA-IR and LAP indices with lower sRAGE means that sRAGE could be indicative of organ fat which may predispose to insulin resistance and metabolic complications before any disease.
Whether the same results are observable also in men need to be explored in future studies.
In conclusion, in obese women without metabolic diseases, lower sRAGE levels reflect accumulation of visceral fat mainly at the epicardial level and are present in advance the appearing of metabolic complications. Due to the role of EAT as an important risk factor for CVDs and the consistent association herein observed with sRAGE in healthy women, sRAGE might be suggested as potential early marker of cardiometabolic risk. This needs to be further confirmed in large-scale population studies. 
